Trial Profile

A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RG 4733 (Primary) ; Vismodegib (Primary)
Indications Alveolar soft part sarcoma; Brain metastases; Chordoma; Clear cell sarcoma; Gastrointestinal stromal tumours; Liposarcoma; Sarcoma
Focus Adverse reactions; Therapeutic Use

02 Feb 2022 Results assessing efficacy of concurrent inhibition of Notch and Hedgehog signaling using the gamma secretase inhibitor (GSI) RO4929097 and the smoothened antagonist vismodegib in unresectable or metastatic sarcoma.published in the Clinical Cancer Research
22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
06 Nov 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com